

Hypertriglyceridemia - Pipeline Insight, 2021

<https://marketpublishers.com/r/H0DAB764117EN.html>

Date: October 2021

Pages: 60

Price: US\$ 2,000.00 (Single User License)

ID: H0DAB764117EN

Abstracts

This report can be delivered to the clients within 3-4 Business Days

DelveInsight's, "Hypertriglyceridemia - Pipeline Insight, 2021," report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in Hypertriglyceridemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Hypertriglyceridemia Understanding

Hypertriglyceridemia: Overview

Hypertriglyceridemia refers to an elevated level of triglycerides (a type of lipid) in the bloodstream, a condition that increases the risk of coronary artery disease. The triglycerides found in our bloodstream are a mixture of triglycerides that have been obtained from the diet and those produced in the body to provide an energy source. Hypertriglyceridemia is often caused or worsened by factors such as obesity, poorly controlled diabetes and a sedentary lifestyle. The most common reasons for hypertriglyceridemia developing are obesity, lack of physical activity, type 2 diabetes, metabolic syndrome and familial hyperlipidemia, a genetic condition that causes high triglycerides and low levels of the "good" cholesterol, HDL (high-density lipoprotein).

'Hypertriglyceridemia - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hypertriglyceridemia pipeline landscape is provided which includes the disease overview and Hypertriglyceridemia treatment guidelines. The assessment part of the report embraces, in depth Hypertriglyceridemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hypertriglyceridemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Hypertriglyceridemia R&D. The therapies under development are focused on novel approaches to treat/improve Hypertriglyceridemia.

Hypertriglyceridemia Emerging Drugs Chapters

This segment of the Hypertriglyceridemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hypertriglyceridemia Emerging Drugs

ARO-APOC3: Arrowhead Pharmaceuticals

ARO-APOC3 is designed to reduce production of Apolipoprotein C-III (apoC-III), a component of triglyceride rich lipoproteins (TRLs) including VLDL and chylomicrons and is a key regulator of triglyceride metabolism. The company believes that knocking down the hepatic production of apoC-III may result in reduced VLDL synthesis and assembly, enhanced breakdown of TRLs, and better clearance of VLDL and chylomicron remnants.

MND-21: Mochida Pharmaceutical

MND-21, a therapeutic agent for hypertriglyceridemia which is being developed in collaboration with Sumitomo Pharmaceuticals (Suzhou) Co., Ltd. in China. Currently, it is in Phase III stage of clinical trial evaluation to treat Hypertriglyceridaemia.

Further product details are provided in the report.....

Hypertriglyceridemia: Therapeutic Assessment

This segment of the report provides insights about the different Hypertriglyceridemia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Hypertriglyceridemia

There are approx. 22+ key companies which are developing the therapies for Hypertriglyceridemia. The companies which have their Hypertriglyceridemia drug candidates in the most advanced stage, i.e. phase III include, Mochida Pharmaceutical.

Phases

DelveInsight's report covers around 22+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Hypertriglyceridemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravenous

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hypertriglyceridemia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hypertriglyceridemia therapeutic drugs

key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hypertriglyceridemia drugs.

Hypertriglyceridemia Report Insights

Hypertriglyceridemia Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Hypertriglyceridemia Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Hypertriglyceridemia drugs?

How many Hypertriglyceridemia drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hypertriglyceridemia?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hypertriglyceridemia therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Hypertriglyceridemia and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Arrowhead Pharmaceuticals

Mochida Pharmaceutical

Ionis Pharmaceuticals

89bio

Regeneron Pharmaceuticals

Acasti Pharma Inc.

Staten Biotechnology BV

NorthSea Therapeutics B.V.

Afimmune

Rivus Pharmaceuticals

Novo Nordisk

Viking Therapeutics

Liminal BioSciences

Matinas BioPharma

Arbutus Biopharma

Better Therapeutics

Key Products

ARO-APOC3

MND-21

IONIS-APOCIII-LRx

BIO89-100

Evinacumab

CaPre

STT-5058

NST-1024

DS102

AKCEA-APOCIII-LRx

NST-4016

BT-005

HU 6

TKM-HTG

COR 003

MAT-9001

VK 1430

PBI 4050

Contents

- Introduction
- Executive Summary
- Hypertriglyceridemia: Overview
 - Causes
 - Mechanism of Action
 - Signs and Symptoms
 - Diagnosis
 - Disease Management
- Pipeline Therapeutics
 - Comparative Analysis
- Therapeutic Assessment
 - Assessment by Product Type
 - Assessment by Stage and Product Type
 - Assessment by Route of Administration
 - Assessment by Stage and Route of Administration
 - Assessment by Molecule Type
 - Assessment by Stage and Molecule Type
- Hypertriglyceridemia – DelveInsight's Analytical Perspective
- Late Stage Products (Phase III)
 - Comparative Analysis
- MND-21: Mochida Pharmaceutical
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report
- Mid Stage Products (Phase II)
 - Comparative Analysis
- ARO-APOC3: Arrowhead Pharmaceuticals
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report
- Early Stage Products (Phase I)
 - Comparative Analysis
- ARGX 116: argenx
 - Product Description
 - Research and Development

Product Development Activities
Drug profiles in the detailed report
Preclinical and Discovery Stage Products
Comparative Analysis
VK 1430: Viking Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report

Inactive Products
Comparative Analysis
Hypertriglyceridemia Key Companies
Hypertriglyceridemia Key Products
Hypertriglyceridemia- Unmet Needs
Hypertriglyceridemia- Market Drivers and Barriers
Hypertriglyceridemia- Future Perspectives and Conclusion
Hypertriglyceridemia Analyst Views
Hypertriglyceridemia Key Companies
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Hypertriglyceridemia

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Hypertriglyceridemia
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Hypertriglyceridemia - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/H0DAB764117EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H0DAB764117EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970